INHIBITEC Anticuerpos S.L. is a pre clinical and clinical stage biotechnology company founded in 2019 in Santander, (Cantabria), Spain, focused on the development of a therapeutic monoclonal antibody (mAB) to be used in cure of autoimmune diseases and more specifically in Psoriasis and Psoriasic Arthritis. 

Our technology is based in a patent owned by the Spanish National Research Council (CSIC) and the Universidad de Cantabria (UC), filled in 2015. Scientists are Jesús Merino PhD, full professor at the UC and Ramón Merino PhD, senior staff Scientist at the CSIC.

Our approach is a novel pathway to increase the efficacy vs current therapies for the treatment of Psoriasis and Psoriatic Arthritis

Our team is formed by multi skilled professionals, coming form the science, Biotech, pharmaceutical and financial industries, with a strong background and experience in the industry